You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

PD1 monoclonal antibody

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Rectal Cancer Trial (Short-course radiotherapy combined with furoquintinib and PD-1 mAb)

Not yet recruiting
  • Rectal Cancer
  • Short-course radiotherapy combined with furoquintinib and PD-1 monoclonal antibody
  • (no location specified)
Aug 29, 2023

Bevacizumab Combined With PD-1 Monoclonal Antibody in

Not yet recruiting
  • Colorectal Cancer
  • Bevacizumab Combined With PD-1 Monoclonal Antibody
  • (no location specified)
Nov 8, 2023

Multiple Cancer, Colorectal Cancer Trial (MSI-H/MSS (dMMR/pMMR) mixed sMPCC: combination of mFOLFOX6+PD-1 mAb neoadjuvant

Not yet recruiting
  • Multiple Cancer
  • Colorectal Cancer
  • MSI-H/MSS (dMMR/pMMR) mixed sMPCC: combination of mFOLFOX6+PD-1 monoclonal antibody neoadjuvant therapy
  • All-MSI-H (dMMR) sMPCC: single-drug PD-1 monoclonal antibody neoadjuvant therapy
  • (no location specified)
Aug 20, 2023

MSS, Rectal Cancer Trial (Sintilimab with Interleukin-2)

Not yet recruiting
  • MSS
  • Rectal Cancer
  • Sintilimab with Interleukin-2
  • (no location specified)
Nov 1, 2023

Colorectal Cancer Trial in Hangzhou (Ametumumab, Anti-PD-1 mAb, Cetuximab)

Not yet recruiting
  • Colorectal Cancer
  • Hangzhou, Zhejiang, China
    Sir Run Run Shaw Hospital, Zhejiang University School of Medicin
Jan 30, 2023

NK-T-Cell Lymphoma, Extranodal Trial in Shanghai (4 cycles of ESA regimen with sandwiched radiotherapy, 2 cycles of ESA regimen

Not yet recruiting
  • NK-T-Cell Lymphoma, Extranodal
  • 4 cycles of ESA regimen with sandwiched radiotherapy
  • +2 more
  • Shanghai, Shanghai, China
    Ruijin Hospital
Sep 29, 2023

Peripheral T-Cell Lymphoma, Not Otherwise Specified, Angioimmunoblastic T-cell Lymphoma Trial in Changchun (Rituximab,

Recruiting
  • Peripheral T-Cell Lymphoma, Not Otherwise Specified
  • Angioimmunoblastic T-cell Lymphoma
  • Changchun, Jilin, China
    The First Bethune Hospital of Jilin University
Apr 7, 2023

Solid Tumors Trial (GS-9911, Zimberelimab)

Not yet recruiting
  • Solid Tumors
  • (no location specified)
Oct 9, 2023

Efficacy of PD-1 Monoclonal Antibody

Recruiting
  • Esophageal Squamous Cell Carcinoma
  • PD-1 Inhibitor
    • Guangzhou, China
      Nanfang Hospital
    Jul 5, 2022

    Malignant Melanomas Trial in Fuzhou (Recombinant Human Adenovirus Type 5 Injection)

    Enrolling by invitation
    • Malignant Melanomas
    • Recombinant Human Adenovirus Type 5 Injection
    • Fuzhou, Fujian, China
      Fujian Cancer Hospital, Department of Internal Medicine, Ward 19
    Jul 7, 2023

    Esophagus Cancer, Bladder Cancer, Liver Cancer Trial (Intravenous injection of P-IL-2, P-IL-2 plus Anti-PD-1 Monoclonal

    Not yet recruiting
    • Esophagus Cancer
    • +4 more
    • Intravenous injection of P-IL-2
    • P-IL-2 plus Anti-PD-1 Monoclonal Antibody
    • (no location specified)
    Apr 24, 2023

    Colorectal Cancer Trial (Serplulimab + FOLFOXIRI, Radiation therapy)

    Not yet recruiting
    • Colorectal Cancer
    • Serplulimab + FOLFOXIRI
    • Radiation therapy
    • (no location specified)
    Oct 24, 2023

    Solid Tumor, Adult Trial in Australia (IOS-1002, IOS-1002 + PD-1 mAb)

    Recruiting
    • Solid Tumor, Adult
    • Clayton, Australia
    • +4 more
    Mar 15, 2023

    Malignant Melanoma, Liver Metastases Trial (Recombinant Human Adenovirus Type 5 Injection,Camrelizumab,Nab-paclitaxel)

    Not yet recruiting
    • Malignant Melanoma
    • Liver Metastases
    • Recombinant Human Adenovirus Type 5 Injection,Camrelizumab,Nab-paclitaxel
    • (no location specified)
    Dec 23, 2022

    Solid Tumor Trial (GS-4528, Zimberelimab)

    Not yet recruiting
    • Solid Tumor
    • (no location specified)
    Apr 21, 2023

    Tumor Trial in Chuo-Ku, Kashiwa (JNJ-63723283, Erdafitinib)

    Completed
    • Neoplasm
    • Chuo-Ku, Japan
    • +1 more
    Nov 3, 2022

    Radiotherapy, PD-1 Inhibitor, Capecitabine Trial in Zhuhai (SBRT radiotherapy + Conventionally fractionated radiotherapy, PD-1

    Recruiting
    • Radiotherapy
    • +3 more
    • SBRT radiotherapy + Conventionally fractionated radiotherapy
    • +2 more
    • Zhuhai, Guangdong, China
      Fifth Affilliated Hospital of Sun Yat-sen University
    Apr 13, 2022

    Cancer of Unknown Primary Trial in Shanghai (Recombinant humanized anti-PD-1 mAb injection)

    Recruiting
    • Cancer of Unknown Primary
    • Recombinant humanized anti-PD-1 monoclonal antibody injection
    • Shanghai, China
      Fudan University Shanghai Cancer Center
    Apr 18, 2022

    NSCLC Trial in Guangzhou (PEF, Anti-PD-1 mAb)

    Recruiting
    • NSCLC
    • PEF
    • Anti-PD-1 monoclonal antibody
    • Guangzhou, Guangdong, China
      The first Affiliated Hospital of Guangzhou Medical University
    Aug 3, 2023

    Colorectal Cancer Metastatic Trial (HLX26, HLX10)

    Not yet recruiting
    • Colorectal Cancer Metastatic
    • (no location specified)
    Oct 14, 2022

    Patients With Advanced Solid Tumors Trial in Shanghai (ICP-189)

    Not yet recruiting
    • Patients With Advanced Solid Tumors
    • Shanghai, Shanghai, China
      Shanghai Pulmonary Hospital
    May 8, 2022

    Hepatocellular Carcinoma Trial in Guangzhou (PD-1 mAb, Radiofequencey or microwave ablation)

    Recruiting
    • Hepatocellular Carcinoma
    • PD-1 monoclonal antibody
    • Radiofequencey or microwave ablation
    • Guangzhou, Guangdong, China
      Sun Yat-sen University Cancer Center
    May 4, 2022

    Breast Cancer Trial in Beijing (Inetetamab, Toripalimab, Albumin-Bound Paclitaxel)

    Not yet recruiting
    • Breast Cancer
    • Beijing, China
      Cancer Hospital Chinese Academy Of Medical Sciences
    Mar 14, 2022

    Renal Cell Carcinoma, Neoadjuvant Trial (Axitinib plus Toripalimab, radical nephrectomy)

    Not yet recruiting
    • Renal Cell Carcinoma
    • Neoadjuvant
    • Axitinib plus Toripalimab
    • radical nephrectomy
    • (no location specified)
    Feb 12, 2023

    Advanced Solid Tumor, Solid Tumor Trial (BGB-26808, Tislelizumab)

    Not yet recruiting
    • Advanced Solid Tumor
    • Solid Tumor
    • (no location specified)
    Aug 7, 2023